Trade Insulet Corporation - PODD CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.38 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023679% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001457% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 263.14 |
| Open | 261.53 |
| 1-Year Change | 55.61% |
| Day's Range | 260.85 - 267.01 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 1, 2025 | 263.14 | 7.29 | 2.85% | 255.85 | 264.43 | 255.85 |
| Mar 31, 2025 | 262.34 | 5.71 | 2.22% | 256.63 | 263.11 | 254.61 |
| Mar 28, 2025 | 258.57 | 0.33 | 0.13% | 258.24 | 260.98 | 255.72 |
| Mar 27, 2025 | 260.21 | -1.24 | -0.47% | 261.45 | 267.74 | 259.99 |
| Mar 26, 2025 | 264.69 | -7.29 | -2.68% | 271.98 | 274.38 | 261.42 |
| Mar 25, 2025 | 272.54 | -1.47 | -0.54% | 274.01 | 275.45 | 268.89 |
| Mar 24, 2025 | 273.81 | 3.91 | 1.45% | 269.90 | 274.69 | 269.90 |
| Mar 21, 2025 | 268.16 | 5.21 | 1.98% | 262.95 | 268.88 | 258.16 |
| Mar 20, 2025 | 265.30 | 1.05 | 0.40% | 264.25 | 269.51 | 263.45 |
| Mar 19, 2025 | 265.50 | 9.46 | 3.69% | 256.04 | 266.63 | 255.99 |
| Mar 18, 2025 | 260.22 | -0.83 | -0.32% | 261.05 | 262.60 | 255.44 |
| Mar 17, 2025 | 261.40 | 9.27 | 3.68% | 252.13 | 262.31 | 252.13 |
| Mar 14, 2025 | 255.30 | 8.84 | 3.59% | 246.46 | 256.93 | 246.46 |
| Mar 13, 2025 | 244.58 | -1.37 | -0.56% | 245.95 | 245.95 | 239.80 |
| Mar 12, 2025 | 248.32 | 0.62 | 0.25% | 247.70 | 254.96 | 247.09 |
| Mar 11, 2025 | 245.18 | 7.98 | 3.36% | 237.20 | 248.00 | 236.45 |
| Mar 10, 2025 | 236.82 | -10.41 | -4.21% | 247.23 | 247.23 | 229.95 |
| Mar 7, 2025 | 251.57 | -7.66 | -2.95% | 259.23 | 259.44 | 246.52 |
| Mar 6, 2025 | 259.53 | -8.57 | -3.20% | 268.10 | 268.66 | 259.10 |
| Mar 5, 2025 | 270.58 | 2.68 | 1.00% | 267.90 | 271.82 | 267.56 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Insulet Corporation Company profile
About Insulet Corporation
Insulet Corporation is primarily engaged in the development, manufacture and sale of its proprietary Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Omnipod), the Omnipod DASHTM Insulin Management System (Omnipod DASH) and its digital mobile Omnipod platform. The Omnipod System features two devices: a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) and a Personal Diabetes Manager (PDM). Users has to fill the Pod with insulin and wear directly on the body. It can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh or lower back. The Pod delivers precise, personalized doses of insulin into the body through a small flexible tube, cannula. PDM is a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Insulet Corporation revenues increased 21% to $1.1B. Net income increased from $6.8M to $16.8M. Revenues reflect Omnipod System segment increase of 24% to $651.5M, International Omnipod segment increase of 17% to $359.9M, United States segment increase of 24% to $738.9M, All Other segment increase of 17% to $359.9M. Net income benefited from IE on Capital Financing decrease of 13% to $36.7M (expense).
Equity composition
Common Stock, $.001 Par, 03/12, 100M auth., 45,670,320 issd. Insiders own 0.45%. IPO: 5/07, 7.7M shs.@ $15 per share by JPMorgan, Merrill Lynch & Co., Thomas Weisel Partners LLC and Leerink Swann & Company. PO:11/07, 4.9M shs. @ $23.25 per share by JP Morgan and Merrill Lynch.
| Industry: | Medical Equipment, Supplies & Distribution (NEC) |
100 Nagog Park
ACTON
MASSACHUSETTS 01720-3440
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com